Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
This trial is active, not recruiting.
|Conditions||arthritis, rheumatoid, spondylitis, ankylosing|
|Treatment||tnf blockers (infliximab, adalimumab, etanercept)|
|Sponsor||University of Sao Paulo|
|Start date||February 2008|
|End date||February 2011|
|Trial size||100 participants|
|Trial identifier||NCT01072058, CapPesq1252/07|
The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Development, deterioration ou improvement of subclinical heart dysfunction
time frame: 0, 6 ,12, 18 and 24 months
Male or female participants from 18 years up to 70 years old.
Inclusion Criteria: - Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers - Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers Exclusion Criteria: - Clinical heart failure - Chagas'disease - Stable or unstable angina - Past history of myocardial infarct - Systemic árterial hypertension (grade 3) - Valvulopathy - Chronic kidney disease
|Official title||Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker|
Call for more information